Search academic texts

Information × Registration Number 0226U001599, (0125U000396) , R & D reports Title Preclinical evaluation of the effectiveness of pharmaceuticals in alleviating the symptoms of post-traumatic stress disorder popup.stage_title Скринінг ефективності низки фармацевтичних препаратів на фоні ПТСР у мишей Head Strilbytska Olha M., Кандидат біологічних наук Registration Date 28-01-2026 Organization Vasyl Stefanyk Precarpathian National University popup.description1 To evaluate the ability of certain pharmaceuticals from different pharmacotherapeutic groups to reduce the symptoms of PTSD using a mouse animal model and to determine the dose- and time-dependent therapeutic effects popup.description2 During the reporting period, a series of preclinical studies were conducted in male C57BL/6J mice to evaluate the efficacy of pharmacological compounds in correcting behavioral disturbances in a model of post-traumatic stress disorder (PTSD). A unified experimental design was applied for all tested compounds, involving PTSD induction by foot electric shocks followed by assessment of behavioral responses using standardized tests. Contextual fear formation was confirmed in the contextual fear conditioning test, after which pharmacological interventions were initiated with subsequent analysis of anxiety-like, depressive-like, and exploratory behaviors. The study evaluated magnesium compounds, vitamin D, α-ketoglutarate, lithium orotate, selegiline, doxylamine, etifoxine, citicoline, and glycine. Administration of α-ketoglutarate partially reduced the number of freezing episodes but did not affect other behavioral parameters. Magnesium compounds at the tested doses exerted an inhibitory effect on locomotor and exploratory activity. Lithium orotate, doxylamine, etifoxine, and glycine did not demonstrate a pronounced therapeutic effect. In contrast, mice treated with selegiline showed reduced anxiety-like behavior. Positive effects were observed following vitamin D administration. A dose of 100 IU/kg did not affect behavioral parameters, whereas increasing the dose to 400 IU/kg resulted in reduced anxiety-like behavior and normalization of the emotional-motivational state of stressed mice. These findings indicate the potential of vitamin D for correcting PTSD behavioral disturbances and justify further biochemical and molecular studies to elucidate its mechanisms of action. During the reporting period, research outputs were also published, including a review article in a Q1 (Scopus-indexed) journal, a chapter in an international monograph, conference abstracts, confirming the scientific novelty and practical relevance of the results. Product Description popup.authors Vladyslav V. Berezovskyi Mariia P. Lylyk Olha M. Strilbytska Myroslava V. Vatashchuk Viktoriia V. Hurza Vitalii P. Derkachov popup.nrat_date 2026-01-28 Close